Last reviewed · How we verify
routine initiation of treatment with Risperdal Consta
routine initiation of treatment with Risperdal Consta is a Small molecule drug developed by Janssen Pharmaceutica N.V., Belgium. It is currently FDA-approved.
Risperdal Consta, marketed by Janssen Pharmaceutica N.V., is a long-acting injectable antipsychotic with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-acting formulation, which enhances patient compliance. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | routine initiation of treatment with Risperdal Consta |
|---|---|
| Sponsor | Janssen Pharmaceutica N.V., Belgium |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- routine initiation of treatment with Risperdal Consta CI brief — competitive landscape report
- routine initiation of treatment with Risperdal Consta updates RSS · CI watch RSS
- Janssen Pharmaceutica N.V., Belgium portfolio CI